close
Add to watchlist
Biovail Corp (BVF) Healthcare, Biotechnology & Drugs
Biovail Corporation, a pharmaceutical company, engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products principally in the United States and Canada. The company focuses on central nervous system disorders, pain management, and cardiovascular diseases. Its products include Xenazine for the treatment of chorea associated with Huntington's disease; Wellbutrin XL for the treatment of depression in adults; Ultram ER for the management of chronic pain in adults; Zovirax Ointment for the management of initial genital herpes; Zovirax Cream for the treatment of herpes labialis; and Cardizem LA that provides blood pressure control. The company also provides Tiazac/Tiazac XC for the treatment of hypertension and angina; Wellbutrin SR for the treatment of depression; Zyban for smoking cessation treatment; Monocor for the treatment of hypertension and congestive heart failure; Retavase, a tissue plasminogen activator used in thrombolytic therapy; Glumetza to control hyperglycemia in adult patients with non-insulin dependent and mature onset diabetes; Ralivia for the management of pain; and Nitoman for the treatment of hyperkinetic movement disorders, such as Huntington's chorea, Hemiballismus, Senile Chorea, Tic and Gilles de la Tourette Syndrome, and Tardive Dyskinesia. Its legacy products comprise Cardizem CD medications in the calcium channel blocker category of cardiovascular drugs; Ativan for the management of anxiety disorders; and Isordil to treat prophylaxis of ischemic heart pain associated with coronary insufficiency. The company's generic products consist of bioequivalent formulations of Cardizem CD, Adalat CC, Procardia XL, Tiazac, Voltaren XR, and Trental. In addition, it offers research, development, and clinical contract research services to third parties. The company was founded in 1983 and is headquartered in Mississauga, Canada.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.00 |
| Volume | 0 |
| Volume Avg | (mio) 3.44 |
| 52 Week High | 27.74 |
| 52 Week Low | 12.91 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | 0.00 |
| EPS change Q/Q | -1000% |
| EPS change Q/Q Yr ago | 40% |
| EPS change Q/Q next Q est | -100% |
| EPS change Y/Y | 61.54% |
| REV change Q/Q | 8.74% |
| REV change Q/Q Yr ago | 23.41% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.37 |
| Dividend Yield | 0% |